Industry and regulatory experts joined session chair and Cytel president, Cyrus Mehta. Read his own presentation: "Adaptive Designs to Demonstrate Risk Reduction in CV Outcome Trials"
Like the sound of 99% confidence in your trial's enrollment plan? Use Cyel's EnForeSys to compare competing enrollment strategies, accurately forecast milestones, and identify problem areas earlier.
Cytel, Amgen, and PSI bring together Industry, government and academia at 2015 Symposium: Bridging the gap between adaptive trial theory and reality.
--Simona Skerjanec, VP Medical Science
The Medicines Company
--Steven B. Ketchum, VP Research and Development
--Joe Heyes, VP
Early Stage Biostatistics Merck
--Dr. Scott Harris, CMO
--Dr. Patrice Rioux, VP, CMO
--Sylvain Nicolas, Global Head Biostatistics Phase 1 Studies